<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818961</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000630617</org_study_id>
    <secondary_id>BMTGG-NSH-756</secondary_id>
    <nct_id>NCT00818961</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer</brief_title>
  <official_title>Reduced Intensity Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Group of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop
      the growth of cancer cells. It may also stop the patient's immune system from rejecting the
      donor's stem cells. The donated stem cells may replace the patient's immune cells and help
      destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted
      cells from a donor can also make an immune response against the body's normal cells. Giving a
      monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate
      after transplant may stop this from happening.

      PURPOSE: This phase II trial is studying the side effects of donor stem cell transplant and
      to see how well it works in treating patients with high-risk hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To evaluate the safety and toxicity of a reduced-intensity conditioning regimen followed
           by allogeneic bone marrow or peripheral blood stem cell transplantation from an
           HLA-matched unrelated donor in patients with high-risk hematologic malignancies.

        -  To evaluate engraftment by peripheral blood chimerism analysis.

        -  To determine the incidence and severity of acute and chronic graft-versus-host disease
           following the transplant.

        -  To examine the possibility of controlling hematologic malignancies by induction of a
           graft-versus-leukemia/tumor effect.

        -  To determine the disease-free survival, relapse, transplant-related mortality, and death
           from all causes.

      OUTLINE:

        -  Reduced-intensity conditioning regimen: Patients receive 1 of 2 conditioning regimens
           according to diagnosis.

             -  Regimen 1 (acute leukemia, myelodysplastic syndromes, myeloproliferative syndrome,
                or chronic myelogenous leukemia): Patients receive fludarabine phosphate IV over 30
                minutes and busulfan IV over 3 hours on days -6 to -3 or orally 4 times daily on
                days -7 to -3.

             -  Regimen 2 (lymphoproliferative malignancies): Patients receive fludarabine
                phosphate IV over 30 minutes and cyclophosphamide IV over 1 hour on days -5 to -3.
                Patients with CD20+ malignancies also receive rituximab IV over 4-6 hours on days
                -13, -6, 1, and 8.

        -  Transplantation: Patients undergo allogeneic bone marrow or peripheral blood stem cell
           transplantation on day 0.

        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive low-dose alemtuzumab
           subcutaneously on days -11 to -9 and tacrolimus IV over 24 hours beginning on day -3 and
           then orally twice daily beginning on day 14 and continuing until day 60, followed by a
           taper until day 180 in the absence of clinically significant GVHD. Patients also receive
           methotrexate on days 1, 3, and 6.

      Patients who exhibit persistent mixed chimerism or disease relapse/progression despite full
      withdrawal of immunosuppression may receive up to 3 donor lymphocyte infusions.

      Blood samples are taken on days 30, 60, and 100 and then every 4 weeks thereafter for
      chimerism studies by PCR analysis.

      After completion of study therapy, patients are followed periodically for up to 60 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated early due to meeting end point with fewer patients than anticipated
  </why_stopped>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at Day 100</measure>
    <time_frame>100 day</time_frame>
    <description>Survival at Day 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of overall survival at 1 year (# of patients who are alive at 1 year post-transplant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality at Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>patients are evaluable for their cause of death at Day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality at 1 Year Post-transplant</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients who died of non-relapse causes at one year. this is in clusive of all patients who were transplanted on study even though only 10 patients died at by 1 year time point. This outcome will be referenced in the donor chimerism outcome. Only 26/36 patients were eligible for this time point as that is all that were alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Donor Chimerism</measure>
    <time_frame>2 years</time_frame>
    <description>Complete donor chimerism (defined as &gt;/= 95% donor cells in peripheral blood CD3+ and CD33+ was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Recovery</measure>
    <time_frame>Day 100</time_frame>
    <description>The number of patients experiencing neutrophil recovery post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>Day 100</time_frame>
    <description>The number of patients experiencing platelet engraftment post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism</measure>
    <time_frame>Day 100</time_frame>
    <description>DLI is used for patients with mixed chimerism following transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant</measure>
    <time_frame>patients were followed for 2 years</time_frame>
    <description>patients experiencing acute graft versus host disease post-transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Chronic Graft Versus Host Disease</measure>
    <time_frame>&gt;100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant</measure>
    <time_frame>4 years</time_frame>
    <description>Patients will be evaluated up to 4 years post transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
    <description>43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Campath</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
    <description>curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>in patients with Cd20+ malignancies: rituximab 375 mg/m*2 day -13. rituximab 1000 mg/m*2 on days, -6, +1, +8.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>For patients with CLL, NHL &amp; HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>5 mg/m2 administered on days +1, +3 and +6</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Prograf; FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>HSCT, allo transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of one of the following hematological malignancies:

               -  CML, with 1 of the following:

                    -  In first CP AND failed imatinib mesylate therapy, defined as failure to
                       obtain a hematologic remission at 3 months or a major cytogenetic response
                       (i.e., Ph+ cells &lt; 35%) at 6 months or demonstrated clonal evolution or
                       disease progression during therapy

                    -  In accelerated phase with &lt; 15% blasts

                    -  In blast crisis that has entered into a second CP following induction
                       chemotherapy

               -  AML, with 1 of the following:

                    -  In second or subsequent complete remission (CR) (i.e., &lt; 5% blasts by
                       morphology, no residual leukemia by flow cytometry, and absence of
                       cytogenetic abnormalities)

                    -  Failed primary induction chemotherapy, but subsequently entered into a CR
                       with ≤ 2 subsequent re-induction chemotherapy treatment(s)

                    -  In first CR with intermediate-risk or poor-risk cytogenetics

               -  ALL with 1 of the following:

                    -  In second or subsequent CR

                    -  In first CR AND presence of t(9;22)

               -  MDS, with the following:

                    -  High-risk disease, defined by IPSS score of ≥ 1.5 at diagnosis AND meets 1
                       of the following criteria:

                         -  ≤ 10% blasts at diagnosis

                         -  In morphologic CR (&lt; 5% blasts) following cytoreductive chemotherapy

               -  CMML, with 1 of the following:

                    -  ≤ 10% blasts at diagnosis

                    -  In morphologic CR (&lt; 5% blasts) following cytoreductive chemotherapy

               -  CLL/PLL with the following:

                    -  Rai stage I-IV disease

                    -  Failed ≥ 1 prior chemotherapy regimen (including fludarabine phosphate) or
                       ASCT

                    -  Documented chemosensitive or stable, non-bulky disease prior to transplant,
                       defined as &lt; 20% bone marrow involvement AND lymph node size &lt; 3 cm in axial
                       diameter

                    -  No bulky tumor masses, elevated lactate dehydrogenase (LDH), B symptoms, or
                       progressive disease prior to transplant

               -  Low-grade non-Hodgkin lymphoma (NHL) (i.e., small lymphocytic lymphoma,
                  follicular center lymphoma [grade 1 or 2], marginal zone lymphoma, or B-cell
                  lymphoma), with the following criteria:

                    -  Failed ≥ 1 prior chemotherapy regimen or ASCT

                    -  Documented chemosensitive or stable, non-bulky disease prior to transplant,
                       defined as &lt; 20% bone marrow involvement AND lymph node size &lt; 3 cm in axial
                       diameter

                    -  Received ≤ 3 prior chemotherapy regimens (monoclonal antibody therapy and
                       involved-field radiotherapy are not considered a prior regimen)

                    -  No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
                       prior to transplant

               -  Mantle cell lymphoma, with the following:

                    -  Failed to achieve remission or recurred after either conventional
                       chemotherapy or ASCT

                    -  Responsive or stable disease to most recent prior therapy

                    -  No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
                       prior to transplant

               -  Intermediate-grade NHL (i.e., follicular center lymphoma [grade 3] or diffuse
                  large cell lymphoma), meeting the following criteria:

                    -  Failed to achieve remission or recurred after either conventional
                       chemotherapy or ASCT

                    -  Documented chemosensitive, non-bulky disease prior to transplant, defined as
                       at least a partial remission to salvage chemotherapy (≥ 50% reduction in
                       diameter of all disease sites)

                    -  No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
                       prior to transplant

               -  Hodgkin lymphoma, with the following:

                    -  Relapsed after prior ASCT OR after ≥ 2 combination chemotherapy regimens and
                       ineligible for ASCT

                    -  Documented chemosensitive, non-bulky disease prior to transplant, defined as
                       at least a partial remission to salvage chemotherapy (≥ 50% reduction in
                       diameter of all disease sites)

                    -  No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
                       prior to transplant

               -  Peripheral T-cell NHL, with the following:

                    -  Failed to achieve remission or recurred after either conventional
                       chemotherapy or ASCT

                    -  Documented chemosensitive, non-bulky disease prior to transplant, defined as
                       at least a partial remission to salvage chemotherapy (≥ 50% reduction in
                       diameter of all disease sites)

                    -  No bulky tumor masses, elevated LDH, B symptoms, or progressive disease
                       prior to transplant

          -  Myeloproliferative syndrome with poor risk features, meeting 1 of the following
             criteria:

               -  &lt; 55 years old AND Lille score of 1

               -  Lille score of 2

               -  HgB &lt; 10 g/dL AND abnormal karyotype

          -  High-risk disease, with 1 of the following:

               -  Age 40-72 years

               -  Any age AND deemed to be at significantly increased risk of morbidity and death
                  following a standard, myeloablative unrelated donor stem cell transplant (e.g.,
                  received extensive prior therapy, including ASCT)

          -  HLA-matched unrelated donor available, with 1 of the following:

               -  8/8 match at HLA-A, B, C, or DR loci by high-resolution genotyping

               -  Single allelic mismatch at either the HLA-B or HLA-C loci donor by
                  high-resolution molecular typing

                    -  No single allelic mismatch at HLA-A or HLA-DR loci

          -  KPS 80-100%

          -  Adapted weighted Charlson Comorbidity Index &lt; 3

          -  Serum creatinine ≤ 2.0 mg/dL

          -  AST or ALT &lt; 3 times upper limit of normal (ULN)

          -  Total bilirubin &lt; 1.5 times ULN

          -  LVEF ≥ 45%

          -  DLCO &gt; 50%

          -  No hypoxia at rest with oxygen saturation &lt; 92% on room air (corrected with
             bronchodilator therapy)

          -  No other severe pulmonary function abnormalities

          -  No HIV infection

          -  No active hepatitis B or C infection that, in the opinion of a gastroenterologist or
             the transplant committee, places the patient at moderate to high risk for developing
             severe hepatic disease

          -  No active opportunistic infection (e.g., fungal pneumonia, tuberculosis, or viral
             infection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott R. Solomon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJ. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000 Apr 1;95(7):2219-25.</citation>
    <PMID>10733488</PMID>
  </reference>
  <reference>
    <citation>Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A, Matthews D, Sanders JE, Storb R, Appelbaum FR, Anasetti C. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000 Aug;26(4):397-404.</citation>
    <PMID>10982286</PMID>
  </reference>
  <reference>
    <citation>Weisdorf DJ, Billett AL, Hannan P, Ritz J, Sallan SE, Steinbuch M, Ramsay NK. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997 Oct 15;90(8):2962-8.</citation>
    <PMID>9376576</PMID>
  </reference>
  <reference>
    <citation>Anderson JE, Anasetti C, Appelbaum FR, Schoch G, Gooley TA, Hansen JA, Buckner CD, Sanders JE, Sullivan KM, Storb R. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol. 1996 Apr;93(1):59-67.</citation>
    <PMID>8611476</PMID>
  </reference>
  <reference>
    <citation>Izutsu K, Kanda Y, Ohno H, Sao H, Ogawa H, Miyazaki Y, Kawa K, Kodera Y, Kato S, Morishima Y, Hirai H; Japan Marrow Donor Program. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood. 2004 Mar 1;103(5):1955-60. Epub 2003 Nov 6.</citation>
    <PMID>14604976</PMID>
  </reference>
  <reference>
    <citation>Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Haematol. 2003 Dec;123(5):886-95.</citation>
    <PMID>14632780</PMID>
  </reference>
  <reference>
    <citation>Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, Nademanee A, Noreen H, King R, Confer D, Kernan NA. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000 Dec 15;96(13):4096-102.</citation>
    <PMID>11110679</PMID>
  </reference>
  <reference>
    <citation>Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998 Apr 2;338(14):962-8.</citation>
    <PMID>9521984</PMID>
  </reference>
  <reference>
    <citation>Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG, Storb R. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004 Aug 15;104(4):961-8. Epub 2004 Apr 27.</citation>
    <PMID>15113759</PMID>
  </reference>
  <reference>
    <citation>Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989 May 1;73(6):1720-8. Erratum in: Blood 1989 Aug 15;74(3):1180.</citation>
    <PMID>2653460</PMID>
  </reference>
  <reference>
    <citation>Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant. 1998 Nov;22(9):835-43. Review.</citation>
    <PMID>9827810</PMID>
  </reference>
  <reference>
    <citation>Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991 Feb 1;77(3):649-53.</citation>
    <PMID>1991174</PMID>
  </reference>
  <reference>
    <citation>Porter DL, Connors JM, Van Deerlin VM, Duffy KM, McGarigle C, Saidman SL, Leonard DG, Antin JH. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999 Apr;17(4):1234.</citation>
    <PMID>10561184</PMID>
  </reference>
  <reference>
    <citation>O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15;82(6):1695-700.</citation>
    <PMID>8400226</PMID>
  </reference>
  <reference>
    <citation>Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15;89(12):4531-6.</citation>
    <PMID>9192777</PMID>
  </reference>
  <reference>
    <citation>Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004 Sep 1;104(5):1550-8. Epub 2004 May 18.</citation>
    <PMID>15150081</PMID>
  </reference>
  <reference>
    <citation>Escalón MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004 Jun 15;22(12):2419-23.</citation>
    <PMID>15197204</PMID>
  </reference>
  <reference>
    <citation>Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan;32(1):28-35.</citation>
    <PMID>14725898</PMID>
  </reference>
  <reference>
    <citation>Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993 Mar 4;328(9):593-602.</citation>
    <PMID>8429851</PMID>
  </reference>
  <reference>
    <citation>Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringdén O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000 Jun 15;95(12):3996-4003.</citation>
    <PMID>10845940</PMID>
  </reference>
  <reference>
    <citation>Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002 Nov 1;100(9):3121-7.</citation>
    <PMID>12384408</PMID>
  </reference>
  <reference>
    <citation>Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G, Waldmann H, Russell NH. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant. 2000 Feb;25(4):411-7.</citation>
    <PMID>10723585</PMID>
  </reference>
  <reference>
    <citation>Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, Russell NH. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004 Jan 15;103(2):428-34. Epub 2003 Sep 11.</citation>
    <PMID>12969983</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>March 22, 2013</results_first_submitted>
  <results_first_submitted_qc>October 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2013</results_first_posted>
  <last_update_submitted>October 28, 2013</last_update_submitted>
  <last_update_submitted_qc>October 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult AML with 11q23 (MLL) abnormalities</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell NHL</keyword>
  <keyword>stage I cutaneous T-cell NHL</keyword>
  <keyword>stage II cutaneous T-cell NHL</keyword>
  <keyword>stage III cutaneous T-cell NHL</keyword>
  <keyword>stage IV cutaneous T-cell NHL</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosal tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>contiguous st II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous st II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous st II adult diffuse sm cleaved cell lymphoma</keyword>
  <keyword>contiguous st II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous st II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous st II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous st II mantle cell lymphoma</keyword>
  <keyword>contiguous st II marginal zone lymphoma</keyword>
  <keyword>contiguous st II small lymphocytic lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous st II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous st II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous st II adult diffuse sm cleaved cell lymphoma</keyword>
  <keyword>noncontiguous st II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous st II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous st II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous st II mantle cell lymphoma</keyword>
  <keyword>noncontiguous st II marginal zone lymphoma</keyword>
  <keyword>noncontiguous st II small lymphocytic lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult gr III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>de novo MDS</keyword>
  <keyword>previously treated MDS</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient on this study was enrolled &amp; transplanted on 6/9/05. The last patient on this study was enrolled &amp; transplanted on 1/5/11.</recruitment_details>
      <pre_assignment_details>No &quot;groups&quot; were assigned. Pts received chemotherapy based on their disease. 39 patients consented to study but 36 patients received protocol treatment. 3 patients were considered screen failures and did not move forward on study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.44" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival at Day 100</title>
        <description>Survival at Day 100</description>
        <time_frame>100 day</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of overall survival at 100 days</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Survival at Day 100</title>
          <description>Survival at Day 100</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of overall survival at 100 days</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 1 Year</title>
        <description>Evaluation of overall survival at 1 year (# of patients who are alive at 1 year post-transplant)</description>
        <time_frame>1 year</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of overall survival at one year post-transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 1 Year</title>
          <description>Evaluation of overall survival at 1 year (# of patients who are alive at 1 year post-transplant)</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of overall survival at one year post-transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality at Day 100</title>
        <description>patients are evaluable for their cause of death at Day 100</description>
        <time_frame>Day 100</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of non-relapse mortality at Day 100</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality at Day 100</title>
          <description>patients are evaluable for their cause of death at Day 100</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of non-relapse mortality at Day 100</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality at 1 Year Post-transplant</title>
        <description>Number of patients who died of non-relapse causes at one year. this is in clusive of all patients who were transplanted on study even though only 10 patients died at by 1 year time point. This outcome will be referenced in the donor chimerism outcome. Only 26/36 patients were eligible for this time point as that is all that were alive.</description>
        <time_frame>1 year</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant. 10 patients died prior to 1 year post-transplant and were eligible for evaluation of non-relapse mortality at 1 year post-transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality at 1 Year Post-transplant</title>
          <description>Number of patients who died of non-relapse causes at one year. this is in clusive of all patients who were transplanted on study even though only 10 patients died at by 1 year time point. This outcome will be referenced in the donor chimerism outcome. Only 26/36 patients were eligible for this time point as that is all that were alive.</description>
          <population>36 patients underwent hematopoietic stem cell transplant. 10 patients died prior to 1 year post-transplant and were eligible for evaluation of non-relapse mortality at 1 year post-transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Donor Chimerism</title>
        <description>Complete donor chimerism (defined as &gt;/= 95% donor cells in peripheral blood CD3+ and CD33+ was measured.</description>
        <time_frame>2 years</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of donor chimerism</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Donor Chimerism</title>
          <description>Complete donor chimerism (defined as &gt;/= 95% donor cells in peripheral blood CD3+ and CD33+ was measured.</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of donor chimerism</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Recovery</title>
        <description>The number of patients experiencing neutrophil recovery post transplant</description>
        <time_frame>Day 100</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of neutrophil recovery</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Recovery</title>
          <description>The number of patients experiencing neutrophil recovery post transplant</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of neutrophil recovery</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Engraftment</title>
        <description>The number of patients experiencing platelet engraftment post-transplant</description>
        <time_frame>Day 100</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of platelet engraftment.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Engraftment</title>
          <description>The number of patients experiencing platelet engraftment post-transplant</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of platelet engraftment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism</title>
        <description>DLI is used for patients with mixed chimerism following transplant</description>
        <time_frame>Day 100</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for donor leukocyte infusions for mixed chimerism following transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism</title>
          <description>DLI is used for patients with mixed chimerism following transplant</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for donor leukocyte infusions for mixed chimerism following transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant</title>
        <description>patients experiencing acute graft versus host disease post-transplant</description>
        <time_frame>patients were followed for 2 years</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of acute graft versus host disease post-transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant</title>
          <description>patients experiencing acute graft versus host disease post-transplant</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of acute graft versus host disease post-transplant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Chronic Graft Versus Host Disease</title>
        <time_frame>&gt;100 days post-transplant</time_frame>
        <population>35 patients survive past 100 days post-transplant and therefore were eligible for evaluation of chronic graft versus host disease</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Chronic Graft Versus Host Disease</title>
          <population>35 patients survive past 100 days post-transplant and therefore were eligible for evaluation of chronic graft versus host disease</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant</title>
        <description>Patients will be evaluated up to 4 years post transplant</description>
        <time_frame>4 years</time_frame>
        <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of VOD post-transplant</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant</title>
          <description>Patients will be evaluated up to 4 years post transplant</description>
          <population>36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of VOD post-transplant</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>All patients received a hematopoietic Stem Cell Transplantation as part of this clinical trial.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>aortic valve endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary/upper respiratory chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>norovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncopal Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>progressive non-oliguric renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral venous thrombosis and hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANC</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>fluid retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>lower extremity edema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>platelet reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>WBC</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardi</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypothyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>steroid induced diabetes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurry vision</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dry eyes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>periorbital edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>visual changes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>watery eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal cramping</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>abdominal discomfort/tenderness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>bloody stool</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>cholecystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>difficulty swallowing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dry heaves</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>esophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>gas pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>GI distress</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hemorrhoids</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>incontinent (stool)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>mouth erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>mouth pain/tenderness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>rectal pain/discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>taste alterations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>tonsillar adenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>vomitting</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal distention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>chest tightness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dizziness/lighheadedness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>facial drooping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>facial swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>feeling &quot;cold&quot;</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>headache/migraine</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>increased thirst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>lip sore</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>loss of balance</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>scratchy throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>shaky</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>swelling of the neck</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>swelling of upper extremities</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>tremors</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>unsteady gait/balance</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>C diff</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>citrobacteria infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>CMV</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>gram positive bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hand foot syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hsv</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>MRSE</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>parainfluenza</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>staph bacteremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>VRE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>night sweats</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>increased creatinine</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>decreased oral intake</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>diaphoresis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hyperphosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypocalemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ankle pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>deconditioned</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hip pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>leg/knee pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>limited range of motion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>muscle spasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>myalgia/arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>shoulder discomfort/pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>steroid myopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>upper extremity weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>memory changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>aggitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>disoriented</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>flat affect</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hallucinations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BK virus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>nocturia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>urinary hesitancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>urinary urgency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BPH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>basilar crackles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>diminished breath sounds</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dyspenea on exertion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>post nasal drip</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pulmonary nodules</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>rhinorrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>seasonal allergies</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>sinus drainage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>sinus pressure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>sinus thickening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>wheezing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>anal/rectal erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>CVC drainage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>CVC pain/tenderness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>erythema at CVC site</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>facial redness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>FUNGAL RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pale skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>PICC line erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>skin abrasion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>skin erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>skin wound</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>shortness of breath with exertion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>swelling at CVC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott R. Solomon, MD</name_or_title>
      <organization>Blood and Marrow Transplant Group of Georgia</organization>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

